Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential Hypertension

Next Previous
Trial Profile

A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential Hypertension

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amosartan plus L (Primary) ; RLD2001-1
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Acronyms HM_APOLLO
  • Sponsors Hanmi Pharmaceutical

Most Recent Events

  • 19 Feb 2025 Status changed from recruiting to completed.
  • 23 Dec 2024 According to a Hanmi Pharmaceutical media release, announced on the 23rd that it has applied for domestic approval for 'HCP1803', the world's first 1/3 low-dose hypertension triple-drug combination drug in phase 3 clinical trials, under the name 'Amosartan Plus L Tablet'.
  • 04 Jun 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top